WO2014057436A3 - Anticancer conjugate - Google Patents

Anticancer conjugate Download PDF

Info

Publication number
WO2014057436A3
WO2014057436A3 PCT/IB2013/059234 IB2013059234W WO2014057436A3 WO 2014057436 A3 WO2014057436 A3 WO 2014057436A3 IB 2013059234 W IB2013059234 W IB 2013059234W WO 2014057436 A3 WO2014057436 A3 WO 2014057436A3
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
conjugate
domain
fusion protein
functional fragment
Prior art date
Application number
PCT/IB2013/059234
Other languages
French (fr)
Other versions
WO2014057436A2 (en
Inventor
Jerzy Szczepan Pieczykolan
Zbigniew Majka
Wojciech STROŻEK
Marlena Maria GAŁĄZKA
Krzysztof Kazimierz Lemke
Anna Maria PIECZYKOLAN
Katarzyna Dorota WICIEJOWSKA
Joanna Adriana JASZCZEWSKA
Przemysław ZIEMKOWSKI
Original Assignee
Adamed Sp. Z O.O.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Sp. Z O.O. filed Critical Adamed Sp. Z O.O.
Publication of WO2014057436A2 publication Critical patent/WO2014057436A2/en
Publication of WO2014057436A3 publication Critical patent/WO2014057436A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Abstract

A conjugate comprises a fusion protein comprising domain (a), which is the functional fragment of a hTRAIL protein sequence, said fragment beginning with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is the sequence of an immunostimulating effector peptide; and the molecule of a chemical compound Z with antiblastic activity, which is linked to the fusion protein directly or by means ofa conjugation linker L. the conjugate is useful in the treatment of cancer diseases.
PCT/IB2013/059234 2012-10-10 2013-10-09 Anticancer conjugate WO2014057436A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PLPL401144 2012-10-10
PL40114412 2012-10-10

Publications (2)

Publication Number Publication Date
WO2014057436A2 WO2014057436A2 (en) 2014-04-17
WO2014057436A3 true WO2014057436A3 (en) 2014-05-30

Family

ID=49780116

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/059234 WO2014057436A2 (en) 2012-10-10 2013-10-09 Anticancer conjugate

Country Status (1)

Country Link
WO (1) WO2014057436A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014141094A1 (en) * 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
JP6772549B2 (en) * 2016-05-23 2020-10-21 Dic株式会社 Polymerizable compounds and optical anisotropics
JPWO2019031614A1 (en) 2017-08-10 2020-07-16 大日本住友製薬株式会社 Antibody drug conjugate containing hemiasterlin derivative
EP4321523A3 (en) * 2017-08-10 2024-04-24 Sumitomo Pharma Co., Ltd. Hemiasterlin derivatives and antibody-drug conjugates including same
US20220125941A1 (en) * 2019-02-13 2022-04-28 Sumitomo Dainippon Pharma Co., Ltd. Hemiasterlin Derivative and Antibody-Drug Conjugate Thereof
CA3127312A1 (en) 2019-02-13 2020-08-20 Sumitomo Dainippon Pharma Co., Ltd. Hemiasterlin derivative having cysteine residue
CN112851647B (en) * 2019-11-28 2023-01-13 中国海洋大学 Brefeldin A derivative and preparation method and application thereof
CN111285828B (en) * 2020-03-11 2022-02-18 中国科学院南海海洋研究所 Compound proximicin and preparation method and application thereof
CN112125918B (en) * 2020-07-16 2021-10-01 中国科学院南海海洋研究所 Aromatic polyketone compounds Talarogyoxanones A and B as well as preparation method and application thereof
CN115304597B (en) * 2022-08-22 2023-10-20 中国科学院深圳先进技术研究院 Beta-carboline compounds and application thereof in preparation of medicines for treating or preventing tumor diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009043900A1 (en) * 2007-10-03 2009-04-09 Covalys Biosciences Ag Drug transfer based on coenzyme a and acyl carrier protein
US20090162290A1 (en) * 2005-09-09 2009-06-25 Therapharm Gmbh Method for the synthesis of penta-pendant enantiomer-pure chelators and process for therapeutically active bioconjugates preparation by a covalent binding thereof
WO2012072815A1 (en) * 2010-12-03 2012-06-07 Adamed Sp. Z O.O. Anticancer fusion protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101678B (en) 1990-12-31 1998-08-14 Akzo Nv Acid labile molecules
DE10310082A1 (en) 2003-03-07 2004-09-16 Ktb Tumorforschungsgesellschaft Mbh Protein-binding doxorubicin peptide derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162290A1 (en) * 2005-09-09 2009-06-25 Therapharm Gmbh Method for the synthesis of penta-pendant enantiomer-pure chelators and process for therapeutically active bioconjugates preparation by a covalent binding thereof
WO2009043900A1 (en) * 2007-10-03 2009-04-09 Covalys Biosciences Ag Drug transfer based on coenzyme a and acyl carrier protein
WO2012072815A1 (en) * 2010-12-03 2012-06-07 Adamed Sp. Z O.O. Anticancer fusion protein

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JINPING L ET AL: "Analysis of monoclonal antibody and immunoconjugate digests by capillary electrophoresis and capillary liquid chromatography", JOURNAL OF CHROMATOGRAPHY, ELSEVIER SCIENCE PUBLISHERS B.V, NL, vol. 735, no. 1, 31 May 1996 (1996-05-31), pages 357 - 366, XP004039030, ISSN: 0021-9673, DOI: 10.1016/0021-9673(95)01054-8 *
JULIA STIEGLMAIER ET AL: "Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 57, no. 2, 31 July 2007 (2007-07-31), pages 233 - 246, XP019561073, ISSN: 1432-0851, DOI: 10.1007/S00262-007-0370-8 *
KREITMAN ROBERT J: "Recombinant Immunotoxins Containing Truncated Bacterial Toxins for the Treatment of Hematologic Malignancies", BIODRUGS: CLINICAL IMMUNOTHERAPEUTICS, BIOPHARMACEUTICALS AND GENE THERAPY, ADIS INTERNATIONAL, FR, vol. 23, no. 1, 1 January 2009 (2009-01-01), pages 1 - 13, XP002711759, ISSN: 1173-8804, DOI: 10.2165/00063030-200923010-00001 *
SHIN J N ET AL: "Generation of a novel proform of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein that can be reactivated by matrix metalloproteinases", EXPERIMENTAL CELL RESEARCH, ACADEMIC PRESS, US, vol. 312, no. 19, 15 November 2006 (2006-11-15), pages 3892 - 3898, XP024945270, ISSN: 0014-4827, [retrieved on 20061115], DOI: 10.1016/J.YEXCR.2006.08.015 *
TEN CATE B ET AL: "A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability", August 2009, LEUKEMIA (BASINGSTOKE), VOL. 23, NR. 8, PAGE(S) 1389-1397, ISSN: 0887-6924, XP002719935 *

Also Published As

Publication number Publication date
WO2014057436A2 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
WO2014057436A3 (en) Anticancer conjugate
WO2013080147A3 (en) Anticancer fusion protein
MX2018011836A (en) Anti-cd70 antibody drug conjugates.
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
EP3906945A3 (en) Nucleic acids encoding human antibodies to sialyl-lewis a
BR112015023418A2 (en) antibody and drug conjugate, antibody or antigen binding fragment, their production processes, their uses, nucleic acid, vector, and host cell
MX337436B (en) Anticancer fusion protein.
WO2013072813A3 (en) Cytotoxic peptides and antibody drug conjugates thereof
NZ607710A (en) 4-1bb binding molecules
WO2015012904A3 (en) Antibody-sn-38 immunoconjugates with a cl2a linker
MX339203B (en) Anticancer fusion protein.
WO2008103693A3 (en) Chemical linkers with single amino acids and conjugates thereof
MX360208B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX360211B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
WO2011003557A8 (en) A complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent
NZ594480A (en) Methods and compositions for diagnosis and treatment of cancer
WO2013098755A3 (en) Anticancer fusion protein
WO2011103567A3 (en) Peptides and methods for inducing cell death
WO2014207708A3 (en) Amino acid and peptide conjugates and conjugation process
WO2010011952A3 (en) Flip death effector domain derived peptides for inducing autophagy
WO2011029008A3 (en) Synbodies to akt1
WO2012143477A3 (en) Anticancer fusion protein
WO2015187811A3 (en) Human monoclonal antibodies to ganglioside gd2
WO2011135222A3 (en) Use of peptides as transporters intended for the internalization of molecules of interest into target cells
MX336727B (en) New conjugated molecules comprising a peptide derived from the cd4 receptor coupled to a polyanionic polypeptide for the treatment of aids.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13808226

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13808226

Country of ref document: EP

Kind code of ref document: A2